Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

ClinicalTrials.gov ID: NCT01095224

Public ClinicalTrials.gov record NCT01095224. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 27, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Regimens Utilizing Recombinant Adenovirus Serotype 35 (rAd35) With HIV-1 Clade A Env Insert and Recombinant Adenovirus Serotype 5 (rAd5) With HIV-1 Clade A or B Env Inserts in Healthy, HIV-1-Uninfected Adults

Study identification

NCT ID
NCT01095224
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Enrollment
180 participants

Conditions and interventions

Conditions

Interventions

  • rAd35 Env A Biological
  • rAd5 Env A Biological
  • rAd5 Env B Biological

Biological

Eligibility (public fields only)

Age range
18 Years to 50 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 31, 2010
Primary completion
Sep 30, 2012
Completion
Jan 31, 2016
Last update posted
Oct 14, 2021

2010 – 2016

United States locations

U.S. sites
8
U.S. states
6
U.S. cities
7
Facility City State ZIP Site status
Alabama CRS Birmingham Alabama 35294
Bridge HIV CRS San Francisco California 94143
The Hope Clinic of the Emory Vaccine Center CRS Decatur Georgia 30030
Brigham and Women's Hospital Vaccine CRS (BWH VCRS) Boston Massachusetts 02115-6110
Columbia P&S CRS New York New York 10032-3732
New York Blood Center CRS New York New York 10065
University of Rochester Vaccines to Prevent HIV Infection CRS Rochester New York 14642
Vanderbilt Vaccine (VV) CRS Nashville Tennessee 37232-2582

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01095224, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 14, 2021 · Synced Apr 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01095224 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →